Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of mosunetuzumab + polatuzumab vedotin versus R-GemOx in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
MOH_2022-03-20_010578Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab and polatuzumab vedotin in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Roche. Started Mar 2022; status: active, not recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2022-03-20_010578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-20_010578.